Flualprazolam
Viewing r1 — May 8, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Flualprazolam is a synthetic depressant of the benzodiazepine class. It is a close chemical relative of alprazolam (Xanax), distinguished by greater potency and a longer duration of action.[1] It works by amplifying the brain's main calming signal — GABA — producing sedation, anxiety relief, and memory suppression.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
alprazolam, all benzodiazepines, alcohol +4 morealprazolam, all benzodiazepines, alcohol, barbiturates, zolpidem, zopiclone, GHB show less
Flualprazolam was first synthesized in 1976 during a broad patent survey of benzodiazepine candidates, but was never selected for medical development.[2] It appeared on unregulated drug markets in 2018 and became one of the most frequently detected designer benzodiazepines in forensic casework worldwide within two years.[3] It is now US Schedule I[4] and internationally controlled, with no approved medical use anywhere.
Subjective effects include anxiety suppression, heavy sedation, muscle relaxation, emotional suppression, and blackouts — partial or total — that erase memory of what happened during intoxication. The experience arrives fast and envelops completely: anxiety dissolves, the body settles, and the mind narrows until memory formation stops. Characteristic unsought effects include false confidence in one's own sobriety, disinhibition, and motor incoordination.
Flualprazolam produces physical dependence with repeated use, and stopping abruptly can trigger seizures — a potentially life-threatening withdrawal. Most documented deaths involve opioids: when the two are combined, they suppress breathing far more powerfully than either alone, and opioids were present in 83% of postmortem cases.[5] No controlled human studies have been conducted — what is known comes from forensic casework, animal research, and structural analogy to alprazolam.
History[edit]
Discovery
Flualprazolam was first synthesized in 1976 by J.B. Hester Jr. during a systematic survey of triazolo-fused benzodiazepine structures, covered by US Patent 3987052A.[2] Alprazolam and triazolam were selected from that patent family and advanced to clinical development. Flualprazolam — the fluorinated variant — was catalogued and never pursued for therapeutic use.
Emergence as a novel psychoactive substance
Flualprazolam surfaced on European drug markets in 2018. Its first published forensic identification came in 2019 — detected in an anesthesia-robbery case in China[6] and in six adolescent intoxications from counterfeit alprazolam tablets in Oregon.[7] By early 2020, a single US forensic laboratory had confirmed it in 197 blood samples,[5] and the UNODC named it one of the two most frequently detected designer benzodiazepines globally.[3]
Scheduling and market shift
The WHO recommended international control in December 2019, and flualprazolam was placed in Schedule IV of the 1971 Convention in 2020.[8] The UK classified it as Class C in 2021,[9] and the US DEA imposed temporary Schedule I in December 2022,[10] made permanent in April 2026.[4] Following scheduling, bromazolam increasingly replaced it as the dominant designer benzodiazepine in some forensic jurisdictions.[11]
The name flualprazolam is a pharmaceutical contraction: flu- marks the fluorine substitution added to alprazolam, the parent compound. It circulated widely as counterfeit Xanax tablets, detected across multiple continents[12] including in UNODC-confirmed falsified tablets containing both flualprazolam and flubromazolam.[13]
Chemistry[edit]
Structure
Flualprazolam is a triazolobenzodiazepine — a standard benzodiazepine with an additional triazole ring fused to its structure. This family includes alprazolam and triazolam.[17] The sole structural difference from alprazolam is a single fluorine atom on the phenyl ring, which increases fat-solubility and resistance to metabolic breakdown.[1]
Molecular properties
| Molecular formula | C₁₇H₁₂ClFN₄ |
| Molecular weight | 326.8 g/mol |
That single fluorine atom roughly doubles both how widely the drug distributes in the body and how long elimination takes, compared to alprazolam in rat studies.[1] Flualprazolam has no chirality center and is not found in distinct mirror-image forms. No published data on long-term storage stability or salt forms have been identified.citation needed
Pharmacology[edit]
Mechanism of action
Flualprazolam binds to the GABA-A — the brain's primary inhibitory channel — and amplifies the calming effect of GABA already present, causing the channel to open more often. This strengthens inhibitory signals across the brain, producing dose-dependent sedation, anxiety relief, muscle relaxation, and memory suppression. Computational modelling classifies it as potent among designer benzodiazepines,[18] and documented effects appear at blood concentrations as low as 4–15 ng/mL.[19][20]
Pharmacokinetics
No controlled human pharmacokinetic studies exist. Oral onset is reported at 20–40 minutes. In rats, flualprazolam had roughly twice the volume of distribution and twice the half-life of alprazolam at equivalent doses.[1] Since alprazolam lasts about 11 hours in humans, flualprazolam's half-life may be 20 hours or longer — though animal-to-human extrapolation carries real uncertainty.inferred A rabbit model showed a detection window of approximately 36 hours.[21]
Metabolism
The liver breaks flualprazolam down through hydroxylation, producing glucuronide conjugates that appear far more abundantly in urine than the parent compound — these are the preferred drug-testing targets.[22] Individual differences in liver enzyme activity may substantially affect processing speed.[22][23] Standard hospital benzodiazepine screens flag flualprazolam, but confirmatory panels often fail to identify it specifically — in one study, it appeared in 11 of 35 specimens initially classified as false-positive screens.[24]
Neuroscience[edit]
Where it acts
Flualprazolam strengthens GABA-mediated inhibition across key brain circuits.inferred In the prefrontal cortex, this slows information processing and produces cognitive blunting. In the amygdala, reduced threat reactivity is the neural basis of anxiety relief. In the hippocampus, suppressed memory consolidation produces the anterograde amnesia that defines moderate-to-high dose experiences.
Why it matters
Benzodiazepines carry a reinforcing property that arises indirectly: they suppress inhibitory neurons in the brain's reward circuit, releasing the brake on dopamine release and driving the compulsive redosing pattern seen with potent designer benzodiazepines.
The false sense of sobriety — feeling functional while severely impaired — has a neurological explanation. Enhanced inhibitory signalling raises the weight of the brain's internal model, suppressing error signals that would normally register impairment.[19]
Key questions about flualprazolam remain unanswered. Whether the fluorine substitution alters the balance of sedation, anxiolysis, and amnesia relative to alprazolam has not been tested. The true human half-life is unknown — the rat estimate of roughly double alprazolam's[1] awaits human confirmation. Extended aftereffects lasting 6–24 hours may point to active metabolites or slow redistribution from tissues.
Subjective Effects[edit]
Flualprazolam produces a rapid, enveloping calm — anxiety dissolves into heavy sedation and the mind narrows until memory formation stops. What defines the experience is not euphoria but erasure: emotional responsiveness flattens, time blurs, and blackouts spanning hours are common at moderate doses and often go unnoticed.
Relative to alprazolam, flualprazolam produces a comparable experience at lower doses with noticeably longer aftereffects. Among designer benzodiazepines, it sits alongside clonazolam and flubromazolam in the high-potency tier — the effects are not qualitatively different from other potent benzodiazepines, just more prolonged and harder to reverse.
Effect Grid
Clear anxiolysis progressing to moderate sedation defines this range. Emotional suppression becomes apparent — a blunting of both positive and negative affect. Thought deceleration is pronounced, with analysis suppression reducing the capacity for complex reasoning. Anterograde amnesia becomes significant: users may have incomplete or absent recall of events during the experience.
Motor control impairment is now obvious — unsteady gait, slurred speech, and impaired coordination are characteristic. Muscle relaxation is substantial. Dizziness may occur, particularly on standing.
Delusions of sobriety often begin at this dose level — users may perceive themselves as functionally normal despite objectively measurable impairment. Compulsive redosing urge is a significant risk, as amnestic effects cause users to forget they have already dosed. Disinhibition may lead to uncharacteristic behaviour.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Visual haze / noise · Visual processing suppression
Physical fatigue · Dizziness · Body high · Nystagmus (eye wobbles) · Breathing alteration · Insomnia · Sexual arousal suppression · Pain suppression · Heart rate perception changes · Yawning · Tactile euphoria · Sexual arousal enhancement · Dry mouth · Headache · Laughter fits · Nausea · Nausea suppression · Appetite enhancement · Restlessness · Vomiting · Seizure threshold reduction · Bodily dissociation
Nystagmus (eye wobbles) · Breathing alteration · Insomnia · Sexual arousal suppression · Pain suppression · Heart rate perception changes · Yawning · Tactile euphoria · Sexual arousal enhancement · Dry mouth · Headache · Laughter fits · Nausea · Nausea suppression · Appetite enhancement · Restlessness · Vomiting · Bodily dissociation
Cognitive fatigue · Focus suppression · Information processing suppression · Thought deceleration · Memory fragmentation · Motivation suppression · Cognitive euphoria · Confusion · Creativity suppression · Language suppression · Suggestibility enhancement · Thought disorganization · Compulsive redosing urge · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Thought deceleration · Memory fragmentation · Motivation suppression · Cognitive euphoria · Confusion · Creativity suppression · Language suppression · Thought disorganization · Compulsive redosing urge · Humor enhancement · Cognitive dysphoria · Amnesia · Delirium
Irritability · Anxiety · Dysphoria · Emotional lability · Paranoia
Emotional lability
Craving · Trust enhancement · Communication enhancement · Social disconnection · Emotional susceptibility · Sociability suppression · Ego inflation · Depersonalization · Derealization · Cognitive disconnection
Emotional susceptibility · Sociability suppression · Ego inflation · Depersonalization · Derealization · Cognitive disconnection
Timeline
Subliminal transition begins. First signs of muscle tension release and a faint shift toward calm emerge before overt anxiolysis.
Anxiolysis builds steadily. Mild sedation and warmth emerge alongside the first hints of cognitive slowing and muscle relaxation.
Full anxiolysis, sedation, and amnesia. Motor control impairment, emotional suppression, and disinhibition reach maximum intensity. Delusions of sobriety may mask the degree of impairment.
Sedation dominates as peak intensity levels off. Amnesia continues. Cognitive and motor impairment remain substantial but stable.
Gradual return of baseline cognition. Sedation wanes and motor coordination slowly improves, though impairment may persist longer than subjective awareness suggests.
Residual sedation, cognitive fog, and possible next-day impairment. Memory of the experience may be fragmented or absent.
⚠ Do not drive or operate heavy machinery for at least 24 hours after use — residual impairment may persist beyond subjective awareness of effects.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 21 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- alprazolam · all benzodiazepines · alcohol
Toxicity
Acute toxicity
No lethal dose data exist for flualprazolam in any species.safety citation needed Clinical cases document sedation, slurred speech, confusion, and mild respiratory depression — the documented adolescent cases all recovered within 6 hours without antidotal treatment.[7]
Forensic death data are extensive. In Sweden and Finland, flualprazolam was detected in 33 deaths and implicated in 13 (39%), predominantly male with a median age of 30.[25] Postmortem blood concentrations in a large US series ranged from 2.0–620 ng/mL,[5] and it was among the most frequently implicated designer benzodiazepines in a review of 141 drug-class deaths.[26]
Flualprazolam is rarely the sole cause of death. Opioids — mostly fentanyl — were co-detected in 83% of postmortem cases.[5] Combining flualprazolam with opioids suppresses breathing far more powerfully than either drug alone.
Organ toxicity
No liver, kidney, or heart toxicity data exist for flualprazolam. Benzodiazepines as a class are not typically associated with direct organ damage at pharmacological doses.
Drug-facilitated crime
Flualprazolam's sub-milligram potency, rapid onset, and powerful amnestic effects have led to its documented use in drug-facilitated sexual assault and robbery.[21][6]
Psychological Risks
Memory formation stops during intoxication (anterograde amnesia) — users may have no recall of events spanning hours.[22][9] The false belief of being sober and functional while severely impaired (delusions of sobriety) is consistently documented in forensic driving cases and represents the primary safety hazard.[19][5]
Uncharacteristic risk-taking, aggression, or impulsive behavior (disinhibition) is documented at clinical concentrations.[22] Rebound anxiety follows cessation in regular users and scales with dose, duration of use, and speed of discontinuation.
Tolerance & Dependence
No flualprazolam-specific studies exist; assessments draw on benzodiazepine class pharmacology.inferred Tolerance to sedative effects builds through changes in GABA-A expression; tolerance to anxiolytic effects develops more slowly. Cross-tolerance is expected with alcohol, other benzodiazepines, barbiturates, and Z-drugs. Flualprazolam's extended half-life[1] may affect tolerance development rate compared to shorter-acting benzodiazepines.inferred
Stopping abruptly causes a withdrawal: rebound effect anxiety, insomnia, tremor, sweating, perceptual disturbances, and — in severe cases — seizures. Seizure risk is the most dangerous withdrawal complication and requires medically supervised tapering. No flualprazolam-to-diazepam equivalence ratio has been established.[27][28]
Drug Interactions
Opioids (critical)
The most dangerous combination. Opioids and flualprazolam both suppress breathing; together they do so far more powerfully than either alone. Opioids were co-detected in 83% of postmortem cases,[5] and flualprazolam was significantly overrepresented in isotonitazene-related overdose deaths.[14][15]
Alcohol and other depressants
Alcohol, other benzodiazepines, barbiturates, Z-drugs, GHB, and gabapentinoids all depress consciousness and breathing through overlapping mechanisms. Combining any of them with flualprazolam risks unconsciousness and respiratory failure.[9]
CYP3A4 inhibitors
Flualprazolam is broken down by the liver enzyme CYP3A4.[22] Drugs that block this enzyme — including ketoconazole, itraconazole, clarithromycin, HIV protease inhibitors, and grapefruit juice — are expected to raise flualprazolam blood levels significantly.inferred
CYP3A4 inducers
Drugs that speed up CYP3A4 — rifampicin, carbamazepine, phenytoin, St John's Wort — accelerate flualprazolam clearance. In physically dependent users, faster clearance could trigger withdrawal including seizures.[22]inferred
Flumazenil
Flumazenil — the benzodiazepine reversal agent — is expected to reverse flualprazolam's effects.inferred In dependent users, it can precipitate acute withdrawal including seizures.
Contraindications
No flualprazolam-specific data exist. The following are inferred from benzodiazepine class pharmacologyinferred:
Absolute:
- Concurrent opioid use — synergistic respiratory depression; 83% of postmortem cases involved opioids[5]
- Severe breathing disorders — GABA activation depresses respiratory drive
- Myasthenia gravis — muscle-relaxant effect may worsen neuromuscular weakness
- Acute narrow-angle glaucoma — benzodiazepine class contraindication
Relative:
- Liver disease — impaired metabolism risks drug accumulation
- Concurrent CYP3A4 inhibitors — risk of dangerously elevated blood levels
- History of substance use disorder — inherent reinforcing properties
- Pregnancy — benzodiazepine class risk; no reproductive data specific to flualprazolam
- Elderly — increased sensitivity, fall risk, prolonged elimination
- Sleep apnoea — respiratory depression may worsen apnoea
Harm Reduction[edit]
Forms & Identification
Flualprazolam is active at sub-milligram doses, making accurate dosing without analytical equipment essentially impossible with raw powder. Counterfeit tablets vary widely — some contain flualprazolam alone, others are mixtures of designer benzodiazepines or entirely different compounds. A tablet that looks identical to pharmaceutical Xanax may contain something with a very different potency, duration, and risk profile.
Fentanyl test strips and reagent kits cannot distinguish between different benzodiazepines. Only laboratory-grade analysis — such as drug-checking programs — can reliably confirm what a tablet contains.
Guidelines
- Never dose from raw powder without a milligram-precision scale (0.001 g). Even with one, sub-milligram precision is unreliable — volumetric dosing (dissolving a known quantity in a measured volume of solvent) is strongly preferred.
- Start with the lowest available dose and wait at least 2 hours before considering redosing. Onset can be delayed, and the long half-life means effects accumulate.
- Store all remaining doses out of reach before the first dose takes effect. Amnesia-driven redosing is the most common pathway to dangerous intoxication.
- Do not combine with opioids, alcohol, or other depressants under any circumstances.
- Do not drive or operate machinery. Impairment persists far longer than users perceive.
- Tell a trusted person what was taken, how much, and when.
Set & Setting
The defining hazard of flualprazolam is the combination of powerful amnesia and false confidence in one's own sobriety. A safe environment is one where impaired judgment cannot lead to driving, dangerous decisions, or unsupervised access to additional doses.
A sober companion who can intervene if redosing begins is the most important environmental safeguard. Compulsive redosing during amnesia — taking more without remembering having taken the first dose — is a frequently reported pattern with potent designer benzodiazepines.
Aftercare & integration. Flualprazolam's extended half-life means residual sedation, impaired coordination, and cognitive fog can persist well beyond the subjective experience. Allow a full day for recovery before driving or making important decisions.
Memory gaps are common and disorienting. If a trusted companion was present, ask them to fill in the timeline. Do not use alcohol or other sedatives during the recovery window — the drug is still clearing and stacking depressants extends the risk period.
If use was a response to anxiety or distress, the time after the drug clears is an opportunity to assess that pattern. Benzodiazepine anxiolysis relieves anxiety temporarily but reinforces avoidance of the underlying cause. Professional support for anxiety management can reduce the drive toward repeated self-medication.
Recovery & Support
Physical dependence on flualprazolam or other designer benzodiazepines requires medical management. Do not stop abruptly — benzodiazepine withdrawal can cause seizures and is potentially life-threatening. A supervised taper under medical guidance, typically using diazepam substitution, is the standard approach.[27][28]
Peer support communities familiar with benzodiazepine withdrawal can provide practical guidance alongside clinical care. Recovery timelines are often longer than expected — anxiety, insomnia, and sensory sensitivity can persist for weeks to months. This is a recognized medical phenomenon, not a personal failing.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognising an emergency:
- Breathing becomes slow, shallow, or stops
- Lips or fingertips turn blue
- Person cannot be woken by loud voice or sternal rub
- Seizure activity (in users who may be in withdrawal)
Immediate steps:
- Call emergency services immediately if breathing is compromised or the person is unresponsive.
- Place the person in the recovery position (on their side, airway open).
- Do not induce vomiting.
- If opioid co-ingestion is suspected, administer naloxone — it will not reverse benzodiazepine effects but may reverse opioid respiratory depression.
- Monitor breathing continuously until help arrives.
What to tell the dispatcher: Name the substance (flualprazolam or designer benzodiazepine), estimated amount, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Reversal agent: Flumazenil reverses benzodiazepine effects but is rarely used outside hospital settings. In dependent users it can trigger seizures. Its use is a clinical decision, not a field intervention.
Legal Status[edit]
Flualprazolam is internationally controlled under Schedule IV of the 1971 Convention on Psychotropic Substances, following WHO recommendation in December 2019 and adoption by the Commission on Narcotic Drugs in 2020.[8] It has no approved medical use in any jurisdiction.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International (UN) | Schedule IV, 1971 Convention on Psychotropic Substances | Adopted 2020; binding on all signatory states[8] |
| United States | Schedule I (Controlled Substances Act) | Emergency Schedule I from December 2022;[10] extended July 2025;[29] permanent Schedule I effective 1 April 2026. Co-scheduled with clonazolam, diclazepam, etizolam, and flubromazolam[4] |
| United Kingdom | Class C, Schedule 1 (Misuse of Drugs Act 1971) | Effective 18 August 2021[9] |
| Australia | Controlled substance | 43 detections in Victoria (2018–2022)[30][28] |
| Canada | Controlled (CDSA) | Benzodiazepines as a class are controlled under the Controlled Drugs and Substances Act |
| European Union | Monitored via EU Early Warning System | Monitored by EMCDDA from 2018; individual member state scheduling varies |
| Nordic countries | Controlled (various national laws) | Detected in forensic cases from 2016–2019[25][31] |
| New Zealand | Controlled (Misuse of Drugs Act 1975) | Detected in counterfeit Xanax tablets[12] |
Legal status changes frequently and varies by jurisdiction. The information above reflects known scheduling as of early 2026 and is not legal advice. Always verify current local law.
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6] ^abQian Z, Liu C, Huang J, Deng Q, Hua Z (2019) Identification of the designer benzodiazepine 8-chloro-6-(2-fluorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine (flualprazolam) in an anesthesia robbery case — Forensic Toxicology doi:10.1007/s11419-019-00501-1